Controversies in the Treatment of Women with Early-Stage Epithelial Ovarian Cancer

  • Christina Fotopoulou
  • Ann Marie Swart
  • Robert L. Coleman


The management of women with apparent early-stage epithelial ovarian cancer presents a wide range of interlinked diagnostic and therapeutic challenges and controversies including surgical staging and surgical and medical treatments. We provide a critical overview of the most debated and controversial aspects of this challenging disease. In surgery, we focus on confidence in initial staging and the impact of under-assessment and undertreatment, the appropriate degree of surgical radicality, and need for lymphadenectomy, as well as the importance of fertility preservation in women with very early disease. We review the evidence for the need for adjuvant therapies and the optimum regimens particularly addressing the impact on younger women and long-term treatment sequelae in survivors.


Overall Survival Fertility Preservation Surgical Staging Gynecologic Oncology Group Adhesive Small Bowel Obstruction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Collins GS, Altman DG. Identifying women with undetected ovarian cancer: independent and external validation of QCancer(®) (Ovarian) prediction model. Eur J Cancer Care (Engl). 2013;22(4):423–9.CrossRefGoogle Scholar
  2. 2.
    Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Oncology FCoG. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105:3–4.CrossRefGoogle Scholar
  4. 4.
    Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322:1021–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S161–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.PubMedCrossRefGoogle Scholar
  7. 7.
    Wright JD, Lewin SN, Deutsch I, et al. Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2011;123(3):467–73.PubMedCrossRefGoogle Scholar
  8. 8.
    SEER_faststats. Stage Distribution (SEER summary stage 2000) for ovarian cancer, all ages, all races, female: 2000–2008.
  9. 9.
    Braicu EI, Sehouli J, Richter R, et al. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer. 2011;105(12):1818–24.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Vergote I, Amant F. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer. Gynecol Oncol. 2006;102:415–7.PubMedCrossRefGoogle Scholar
  11. 11.
    du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010;28(27):4162–9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23.
  12. 12.
    Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331–8.PubMedCrossRefGoogle Scholar
  13. 13.
    du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23.
  14. 14.
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128(2):252–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Dizon DS, Restivo A, Lomme M, et al. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Am J Clin Oncol. 2008;31(1):39–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Timmers PJ, Zwinderman AH, Coens C, et al. Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer. 2010;46(5):880–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Kumar Dhingra V, Kand P, et al. Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach. Womens Health (Lond Engl). 2012;8(2):191–203.CrossRefGoogle Scholar
  20. 20.
    Garcia-Soto AE, Boren T, Wingo SN, Heffernen T, Miller DS. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol. 2012;206(3):242.e1–5.Google Scholar
  21. 21.
    Shroff R, Brooks RA, Zighelboim I, et al. The utility of peritoneal biopsy and omentectomy in the upstaging of apparent early ovarian cancer. Int J Gynecol Cancer. 2011;21(7):1208–12.PubMedGoogle Scholar
  22. 22.
    Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al., EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003;95(2):113–25.Google Scholar
  23. 23.
    Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19(13):4059–67.PubMedCrossRefGoogle Scholar
  24. 24.
    Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol. 2012;125(2):483–92.PubMedCrossRefGoogle Scholar
  25. 25.
  26. 26.
    Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol. 2002;85:351–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Powless CA, Bakkum-Gamez JN, Aletti GD, et al. Random peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration. Gynecol Oncol. 2009;115(1):86–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Benedetti-Panici P, Greggi S, Maneschi F, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol. 1993;51(2):150–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Petru E, Lahousen M, Tamussino K, et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994;170(2):656–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Onda T, Yoshikawa H, Yokota H, et al. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer. 1996;78(4):803–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Baiocchi G, Grosso G, di Re E, et al. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. Gynecol Oncol. 1998;69(2):151–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Suzuki M, Ohwada M, Yamada T, et al. Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol. 2000;79(2):305–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Nomura H, Tsuda H, Susumu N, et al. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(3):341–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Maggioni A, Benedetti Panici P, Dell’Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95(6):699–704.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
  36. 36.
    Musumeci R, Banfi A, Bolis G, et al. Lymphangiography in patients with ovarian epithelial cancer. Cancer. 1977;40:1444–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Burghadt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40:103–6.CrossRefGoogle Scholar
  38. 38.
    Rungruang B, Miller A, Richard SD, et al. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;124(1):53–8. doi: 10.1016/j.ygyno.2011.09.024.PubMedCrossRefGoogle Scholar
  39. 39.
    Ditto A, Martinelli F, Reato C, et al. Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study. Ann Surg Oncol. 2012;19(12):3849–55. doi: 10.1245/s10434-012-2439-7.PubMedCrossRefGoogle Scholar
  40. 40.
    Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116:269–73.PubMedCrossRefGoogle Scholar
  41. 41.
    Kleppe M, Wang T, Van Gorp T, et al. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123(3):610–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Powless CA, Aletti GD, Bakkum-Gamez JN, et al. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122(3):536–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17(6):1238–44.PubMedCrossRefGoogle Scholar
  44. 44.
    Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009;208(4):614–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94(3):650–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Schaafsma BE, van der Vorst JR, Gaarenstroom KN, et al. Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer. Gynecol Oncol. 2012;127(1):126–30. doi: 10.1016/j.ygyno.2012.07.002.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Fotopoulou C, Braicu I, Sehouli J. Fertility-sparing surgery in early epithelial ovarian cancer: a viable option? Obstet Gynecol Int. 2012;2012:238061. doi: 10.1155/2012/238061.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Satoh T, Hatae M, Watanabe Y, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol. 2010;28(10):1727–32.PubMedCrossRefGoogle Scholar
  49. 49.
    Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997;104(9):1030–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2011;122(2):334–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Kwon YS, Hahn HS, Kim TJ, et al. Fertility preservation in women with early epithelial ovarian cancer. J Gynecol Oncol. 2009;20(1):44–7. doi: 10.3802/jgo.2009.20.1.44.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Borgfeldt C, Iosif C, Måsbäck A. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2007;134(1):110–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Kajiyama H, Shibata K, Mizuno M, et al. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 2011;105(9):1288–94.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible? Hum Reprod. 2011;26(12):3297–302.PubMedCrossRefGoogle Scholar
  55. 55.
    Kajiyama H, Shibata K, Suzuki S, et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol. 2010;36(4):404–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in women with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116(6):1462–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Park JY, Kim DY, Suh DS, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol. 2008;110(3):345–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87(1):1–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm (ICON) collaborators. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in patients with early-stage ovarian cancer. J Natl Cancer Inst. 2003;95(2):125–32.PubMedCrossRefGoogle Scholar
  60. 60.
    Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105–12.PubMedCrossRefGoogle Scholar
  61. 61.
    Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2012;3:CD004706.PubMedGoogle Scholar
  62. 62.
    Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, Ledermann J, Colombo N, Swart AM. On behalf of the ICON1 collaborators. Optimal treatment of early-stage ovarian cancer (in press).Google Scholar
  63. 63.
    Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Chan J, Fuh K, Shin J, et al. The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? Br J Cancer. 2008;98:1191–6.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Chan JK, Tian C, Monk BJ, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008;112:2202–10.PubMedCrossRefGoogle Scholar
  66. 66.
    Trope C, Kaern J, Hogberg T, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol. 2000;11:281–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol. 1993;169:40–52.PubMedCrossRefGoogle Scholar
  68. 68.
    Skirnisdottir I, Sorbe B, Karlsson M, et al. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma. Int J Oncol. 2001;19:1295–302.PubMedGoogle Scholar
  69. 69.
    Obermair A, Fuller A, Lopez-Varela E, et al. A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol. 2007;104:607–11.PubMedCrossRefGoogle Scholar
  70. 70.
    Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Trimbos B, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst. 2010;102:982–7.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351–7.PubMedCrossRefGoogle Scholar
  73. 73.
    International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505–15.CrossRefGoogle Scholar
  74. 74.
    Adams G, Zekri J, Wong H, et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG. 2010;117:1459–67.PubMedCrossRefGoogle Scholar
  75. 75.
    Metzger-Filho O, Moulin C, D’Hondt V. First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions. Curr Opin Oncol. 2010;22(5):513–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Elit L, Chambers A, Fyles A, et al. Systematic review of adjuvant care for women with stage I ovarian carcinoma. Cancer. 2004;101:1926–35.PubMedCrossRefGoogle Scholar
  77. 77.
    Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;102:432–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 Cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:301–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122:89–94.PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Vergote IB, Vergote-De Vos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer. 1992;69(3):741–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol. 1995;6(9):887–93.PubMedGoogle Scholar
  82. 82.
    du Bois A, Herrstedt J, Hardy-Bessard AC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010;28(27):4162–9. doi: 10.1200/JCO.2009.27.4696.PubMedCrossRefGoogle Scholar
  83. 83.
    Bakkum-Gamez JN, Richardson DL, Seamon LG, et al. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010;20(7):1125–31.PubMedCrossRefGoogle Scholar
  84. 84.
    Katsumata N, Yasuda M, Takahashi F, et al., Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–8.Google Scholar
  85. 85.
    Katsumata N, Yasuda M, Seiji Isonishi S, et al. Japanese Gynecologic Oncology Group. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol. 2012;30: (suppl; abstr 5003).Google Scholar
  86. 86.
    Armstrong DK, Bundy B, Wenzel L, et al., Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.Google Scholar
  87. 87.
    Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.PubMedCrossRefGoogle Scholar
  88. 88.
    Trimbos JB. Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer. 2000;10(S1):8–11.PubMedCrossRefGoogle Scholar
  89. 89.
    Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Union for International Cancer Control (UICC), Wiley-Blackwell; 2009.Google Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Christina Fotopoulou
    • 1
  • Ann Marie Swart
    • 2
  • Robert L. Coleman
    • 3
  1. 1.Gynaecological OncologyWest London Gynaecological Cancer Center and Ovarian Cancer Action Research Center, Imperial College LondonLondonUK
  2. 2.Norwich Clinical Trials UnitNorwich Medical School, University of East AngliaNorwichUK
  3. 3.Gynecologic Oncology and Reproductive MedicineUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations